ClinicalTrials.gg
RecruitingNCT07610837BRAVOUpdated Nov 3, 2026

Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis

A Phase 2 interventional study of AZD2389 and Placebo in Liver Fibrosis and Hepatic Cirrhosis, sponsored by AstraZeneca. Recruiting at 22 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 3, 2026First site in Puerto Rico2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Liver Cirrhosis by AstraZeneca — 1 open to participants now, 1 under way, none of them phase 3. Liver Cirrhosis · AstraZeneca.

Planned enrollment
3rd of 11
104 · median 40
Started
2026
the only one that year
Phase 2
6 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Liver Cirrhosis by AstraZeneca, this one is the 3rd largest by planned enrollment, is the only one that started in 2026, is one of 6 in phase 2, and was the 11th registered.

Liver Cirrhosis

1,302 studies on the registry are indexed under Liver Cirrhosis; 340 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

1 of the 11 studies in Liver Cirrhosis by AstraZeneca is open now, in 2 countries.

By country, each count listing its studies:

Who these studies take

Of the 207 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 65 (31%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Liver Cirrhosis by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.

Read the detailed description

Study details include:

  • The study duration will be approximately 32 weeks, including screening duration of 4 weeks, the treatment duration of up to 24 weeks, and follow-up period of 4 weeks.
  • The visit frequency will be approximately every 4 weeks except from Visit 2 to Visit 4, which is every 2 weeks.

Disclosure Statement:

This is a parallel group treatment study that is blinded to the participants and investigators.

Number of Participants:

Approximately 230 participants with SLD and advanced fibrosis will be screened such that approximately 104 participants will be randomised. Approximately 52 participants will be randomised to receive AZD2389 and approximately 52 participants will receive placebo.

Note: 'Screened' means a participant's, or their legally authorised representative's, agreement to participate in a clinical study following completion of the informed consent process.

Study Arms and Duration:

Arm A will include 52 participants with SLD and advanced fibrosis who will receive oral AZD2389 for 24 weeks. Arm B will include 52 participants with SLD and advanced fibrosis who will receive oral placebo for 24 weeks.

03

Conditions studied

  • Liver Fibrosis
  • Hepatic Cirrhosis

Browse trials for

Keywords

  • Liver Fibrosis
  • Hepatic Cirrhosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Males/females aged 18 or over
  • A diagnosis of SLD with advanced fibrosis
  • No significant change in weight over the last 6 months
  • us by participants or participants partners
  • Capable of giving
  • Judged by the investigator to be suitable for study

Key Exclusion Criteria:

  • Portal hypertension (LSM >25 kPa or 20-25 kPa with \<150×10⁹/L), decompensated liver disease, >A6, MELD >12, other chronic liver diseases, prior/planned liver transplant, or malignant liver tumors.
  • Positive viral infections, including or , or unless HCV RNA-negative ≥12 weeks after treatment.
  • Alcohol intake above protocol thresholds, or positive screen for drugs of abuse.
  • Significant metabolic, cardiovascular, or GI disorders, including T1DM or insulin-treated T2DM, uncontrolled hypertension, recent major cardiac/cerebrovascular events, severe heart failure, serious arrhythmias, significant pancreatic disease, or major GI surgery.
  • History of psychosis, bipolar disorder, recent major depression, or suicide attempt/ideation within 1 year.
  • Bleeding risk or wound-healing concerns, including coagulation disorders, major bleeding history, active wounds or recent major surgery, or severe dermatologic immune conditions.
  • Prohibited medications or , including moderate/strong or BCRP/OAT3 inhibitors/inducers, anticoagulants/antiplatelets (except aspirin ≤81 mg/day), or hypersensitivity to DPP4 inhibitors.
  • Other protocol-defined exclusions, including significant abnormal labs (e.g., worsening /AST), recent participation in another IMP study, or investigator judgment of unsuitability.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Arm A

    Doses of AZD2389 to be administered orally.

    Drug: AZD2389

  • Placebo comparator
    Arm B

    Doses of placebo to be administered orally.

    Other: Placebo

Interventions

  • potent, selective, first-in-class, small molecule oral inhibitor of FAP and is being developed for the treatment of CLDs with advanced hepatic fibrosis including cirrhosis.

    Also known as: Active IMP

  • OtherPlacebo

    Oral administration

06

What researchers measure

Primary outcomes

  1. Absolute change in Enhanced Liver Fibrosis (ELF) score from baseline to week 24

    To evaluate the effects of AZD2389 versus placebo on improvement in ELF score. Lowered ELF scores would suggest better outcome. Note: ELF is not bounded, i.e. there are no minimum and maximum values

    Time frame: 24 weeks

  2. Reported quantity and severity of adverse events (AEs)

    To assess the safety and tolerability of AZD2389 in participants with SLD and advanced fibrosis

    Time frame: Up to and including Day 197

  3. Number of participants with observed changes in blood pressure against baseline mmHg value

    Assess blood pressure level (with systolic and diastolic pressure) in mmHg

    Time frame: Up to and including Day 197

  4. Number of participants with identified abnormalities in results of 12-lead safety electrocardiograms (ECG)

    12-lead safety ECG (PR interval, QRS complex, ST interval, T wave)

    Time frame: Up to and including Day 197

  5. Number of participants with abnormal laboratory results detected in urine samples

    Urinalysis - Paper chromatography

    Time frame: Up to and including Day 197

  6. Number of participants with observed changes in heart rate (BPM) against baseline value

    Pulse rate measured in beats per minute (BPM)

    Time frame: Up to and including Day 197

  7. Number of participants with observed changes in Sp02 oxygen values against baseline measurement

    Sp02 oxygen saturations measured by percentage

    Time frame: Up to and including Day 197

  8. Number of participants with observed changes in body temperature against baseline value

    Body temperature measured in degrees Celsius

    Time frame: Up to and including Day 197

  9. Number of participants with observed changes in respiratory rate against baseline value

    Respiratory rate measured in respirations per minute

    Time frame: Up to and including Day 197

  10. Number of participants with abnormal laboratory test results detected in blood samples

    Hematology - Platelets (x10\^9/L)

    Time frame: Up to and including Day 197

  11. Number of participants with abnormal laboratory test results detected in blood samples

    Coagulation - INR

    Time frame: Up to and including Day 197

  12. Number of participants with abnormal laboratory test results detected in blood samples

    Clinical Chemistry - ALT (U/L)

    Time frame: Up to and including Day 197

  13. Number of participants with abnormal laboratory test results detected in blood samples

    Fibrinolysis - D-dimer (ng/mL fibrinogen-equivalent units)

    Time frame: Up to and including Day 197

  14. Number of participants with abnormal laboratory test results detected in blood samples

    Clinical Chemistry - AST (U/L)

    Time frame: Up to and including Day 197

  15. Number of participants with abnormal laboratory test results detected in blood samples

    Clinical Chemistry - ALP (U/L)

    Time frame: Up to and including Day 197

Secondary outcomes

  1. Absolute change in Procollagen Type III N-terminal Propeptide (ProC3) from baseline to week 24

    To assess the effects of AZD2389 versus placebo on improvement in ProC3

    Time frame: 24 weeks

  2. Absolute change in Liver Stiffness Measurement (LSM) from baseline to week 24

    To assess the effects of AZD2389 versus placebo on improvement in LSM measured by Vibration-controlled transient elastography (VCTE)

    Time frame: 24 weeks

  3. Absolute change in Controlled Attenuation Parameter (CAP) from baseline to week 24

    To assess the effects of AZD2389 versus placebo on improvement in CAP

    Time frame: 24 weeks

  4. Percentage change in Procollagen Type III N-terminal Propeptide (ProC3) from baseline to week 24

    To assess the effects of AZD2389 versus placebo on improvement in ProC3

    Time frame: 24 weeks

  5. Percentage change in Liver Stiffness Measurement (LSM) from baseline to week 24

    To assess the effects of AZD2389 versus placebo on improvement in LSM measured by Vibration-controlled transient elastography (VCTE)

    Time frame: 24 weeks

07

Study locations

22 of 22 sites recruiting
  • Research Site
    Chandler, Arizona 85224, United States
    Recruiting
  • Research Site
    Tucson, Arizona 85712, United States
    Recruiting
  • Research Site
    Fresno, California 93720, United States
    Recruiting
  • Research Site
    Jupiter, Florida 33458, United States
    Recruiting
  • Research Site
    Miami, Florida 33122, United States
    Recruiting
  • Research Site
    Port Orange, Florida 32127, United States
    Recruiting
  • Research Site
    Kansas City, Missouri 64131, United States
    Recruiting
  • Research Site
    St Louis, Missouri 63123, United States
    Recruiting
  • Research Site
    Las Vegas, Nevada 89106, United States
    Recruiting
  • Research Site
    Morehead City, North Carolina 28557, United States
    Recruiting
  • Research Site
    Raleigh, North Carolina 27607, United States
    Recruiting
  • Research Site
    Westlake, Ohio 44145, United States
    Recruiting
  • Research Site
    Yukon, Oklahoma 73099, United States
    Recruiting
  • Research Site
    Clarksville, Tennessee 37040, United States
    Recruiting
  • Research Site
    Austin, Texas 78757, United States
    Recruiting
  • Research Site
    Denison, Texas 75020, United States
    Recruiting
  • Research Site
    Georgetown, Texas 78626, United States
    Recruiting
  • Research Site
    Houston, Texas 77004, United States
    Recruiting
  • Research Site
    Houston, Texas 77079, United States
    Recruiting
  • Research Site
    San Antonio, Texas 78215, United States
    Recruiting
  • Research Site
    San Antonio, Texas 78222, United States
    Recruiting
  • Research Site
    San Juan, 00927, Puerto Rico
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jul 2027, 14 months after the start.

Of 28 industry-sponsored phase 2 interventional studies under Liver Cirrhosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 27. This study's planned 14 months is below that.

Counting every sponsor, half of 55 studies reached it within 27 months; a quarter within 19 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 28, 2026
StartActual
May 7, 2026
Primary completionEst.
Jul 7, 2027
CompletionEst.
Jul 7, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added — first site in Puerto Rico
Show 2 added (1 Puerto Rico, 1 United States)
  • Research Site · San Juan, Puerto Rico
  • Research Site · Fresno, United States
across 2 updates, Oct 19, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    1 site added
    Show site
    • Research Site · Fresno, United States
    + 1 other change: verification date
  2. Oct 19, 2026
    1 site added — first site in Puerto Rico
    Show site
    • Research Site · San Juan, Puerto Rico
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07610837
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 28, 2026
Start date
May 7, 2026
Primary completion
Jul 7, 2027 (estimated)
Completion
Jul 7, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD2389

Start the discussion